Orgovyx - (120 mg ; Tablet)

Generic Name	Relugolix	Innovator	Sumitomo Dainippon
Dosage	120 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events